Novel Maintenance Combination in Advanced Ovarian Cancer

The FDA granted RMAT status to gemogenovatucel-T for maintenance in patients with advanced ovarian cancer.

In season 2, episode 6 of Targeted Talks, Alexander B. Olawaiye, MD leads a discussion with Haider S. Mahdi, MD, about the modern approaches to treating cervical and endometrial cancers.

Potential practice-changing therapies in gynecologic cancer include the emergence of carboplatin, paclitaxel, and PD-1 blockade, or the use of fam-trastuzumab deruxtecan-nxki in endometrial cancer.

Sarah M. Temkin, MD leads discussion with Daphne B. Stewart, MD, around targeted therapies in ovarian cancer, whether offered in the academic or community setting.

Mass spectrometry and machine learning show promise for early cancer detection and prognosis by analyzing metabolic signatures.

DeepHRD predicted homologous recombination deficiency with greater accuracy than FDA-approved standard molecular tests.